Healthcare Industry China Bioprocess Instruments Market | Page 2

Your Catalyst To a Lucrative Business
With the patents of numerous biopharmaceutical products expiring by 2016, the market is anticipated to
provide a lucrative opportunity for contract manufacturers operating in the region. Approval of the trail plan
for new drug marketing authorization holder (MAH) in 2016 to produce, conduct clinical trials, and market
the products is expected to provide an impetus to the growth of the industry over the next few years.
Increasing demand for bioprocess instruments in the pharmaceutical, research & development, industrial and
medical laboratories coupled with the increasing number of these facilities is expected to result in the growth
of the market. Change in lifestyle & food consuming habits, and growing levels of air & water pollution have
led to increasing occurrence of disease including obesity which has resulted in a rising number of patients
diagnosed with cancer, heart disease, diabetes and other chronic conditions. Thus, the healthcare sector is
anticipated to create demand for treatment and laboratory services, which will result in the growth of
bioprocess instruments market over the forecast period.
Stringent regulatory policies and the high cost of instruments are likely to restrain the bioprocess instruments
market in China. The government has been focusing on reducing the fragmentation in the industry by
consolidating manufacturers that lack standards in production with larger companies. This move will help in
preventing the quality risks and sub-par manufacturers entering the market. Shortage of skilled labor is
another challenge in the growth of bioprocessing industry.
Koninklijke Philips N.V., Thermo Fisher Scientific Inc. and Becton, Dickinson and Company were the top three
companies in the market in China in 2016. Companies are extensively investing in R&D for innov ation and
new product development. In addition, companies are adopting the strategy of merger and acquisition to
expand their product portfolio.
Hexa Research has segmented the China bioprocess instruments market based on type:
Segmentation by type, 2014 - 2024 (USD Million)
• Cell Expansion
• Flow Cytometry
• Biologics Safety Testing
• Cell Line Development
• Tangential Flow Filtration
• Cell Counters
• Virus Filtration
• Cell Culture
• Pyrogen Testing
Follow Us: